They power through fibroids.
But at what cost?
Painful, heavy periods are common but not normal.
Uterine fibroids may cause these and other debilitating symptoms that significantly impact
quality of life, fertility, relationships, careers and finances.
Altin Biosciences develops first-in-class
botanical drug candidates for global unmet medical needs.
First-in-class, non-hormonal ABC-105/205 is for the treatment of uterine fibroids and is designed to be both fertility and pregnancy-friendly. This represents a paradigm shift in the treatment of uterine fibroids and a significant opportunity to improve the lives of females, reduce reliance on hysterectomy for fibroids, and positively impact fertility and maternal mortality worldwide.
Medical breakthrough for fibroids: ABC-105/205
| Rigorous studies | Synergistic results | Botanically derived |
Ground-breaking research on ABC-105/205, conducted by Dr. Ayman Al-Hendy at the University of Chicago in 2022, was recently published in the medical journal Fertility & Sterility Science.
Research shows the patent-pending combination of natural compounds crinum latifolium (Crila®) and epigallocatechin gallate (EGCG) showed enhanced antiproliferative (suppresses cell growth) effects and apoptosis (cell death) on human uterine fibroid cells compared to single treatments.
Seed to science
Our drug candidates are subject to FDA regulation.
Pre-clinical and clinical trials will evaluate safety and efficacy as required for all FDA-licensed drugs.
The hypothesis we are testing:
ABC-105/205:
• shrinks and may eliminate uterine fibroids
• is fertility and pregnancy-friendly
• provides an effective alternative to invasive surgery
